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hat Do We Really Know?
n the recent paper by Tachjian et al. (1), the investigators
ighlight several important points concerning the use of herbal
upplements: 1) their use is widespread, especially among certain
mportant subgroups, such as patients taking prescription medica-
ions; 2) disclosure of complementary and alternative medicine use
y patients to their physicians remains low; and 3) potentially
angerous herb-drug interactions may be missed. I applaud the
nvestigators for undertaking a topic that is important not only for
atients with cardiovascular diseases but also for those with cancer
nd other chronic diseases. However, a variety of shortcomings in
heir methods and conclusions detract from the overall importance
f their message.
The conclusion that “herbal remedy use is increasing dramati-
ally” (1) is overstated. In fact, the use of complementary and
lternative medicine therapies by U.S. adults appears to have
eveled off in the years between the 2002 and 2007 National
ealth Interview Surveys (2,3). Although the use of a few
omplementary and alternative medicine therapies was noted to
ave increased in the interim, herbal supplements were not among
hose named. More important but missing from the investigators’
eview, however, is that an estimated 15 million adults in 1997
oncurrently took prescription medications with herbal remedies
r high-dose vitamin supplements (4).
The discussion of herb and drug metabolism is oversimplified
nd potentially misleading. For example, the investigators imply
hat cytochrome P450 (CYP) 3A4 is responsible for over 50% of all
rescription medication metabolism. Although 50% may be an
verstated estimate of the contribution of CYP 3A4 (5), more
mportant is to understand that clinical consequences of CYP 3A4
nhibitors are most likely to be observed for drugs that are solely (or at
east mainly) metabolized by CYP 3A4; additionally, inhibitory effects
re dependent on the amount of inhibition achieved. So, for example,
lthough the investigators’ Table 2 (1) correctly identifies sertraline
nd fluoxetine as CYP 3A4 substrates, sertraline is metabolized
rimarily by CYP 2C9 and fluoxetine by CYP 2D6. Additionally,
oth drugs are considered weak inhibitors of CYP 3A4.
Finally, important studies were missed or left out of the
nvestigators’ systematic review. For example, although hawthorn
Crataegus spp.) is thought to enhance the activity of digitalis, the
nly study to examine the potential interaction between the 2
gents in humans (6) concluded that there were no differences in
tandard pharmacokinetic parameters for digoxin with or without
oncurrent hawthorn administration. Contrary to the investigators’
ssertion that no systematic safety assessments of hawthorn exist,
systematic review of the adverse event profile of hawthorn pooled
ata from 5,577 patients and concluded that adverse events were
ncommon and most often mild; there were no reports of drug
nteractions or deaths (7). The only evidence of a hawthorn–
igitalis interaction is based on a few studies in rat and guinea pig syocytes; there are no case reports (8). The perpetuation of a
awthorn–digitalis interaction is a result of the investigators’ citing
eviews rather than primary publications.
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mportance of Providing
ardiologists With Useful
dvice on Herb-Drug Interactions
he American Herbal Products Association agrees with the
mportance Tachjian et al. (1) placed on doctor-patient commu-
ication and education. Since 2001, the American Herbal Prod-
cts Association has recommended that consumers tell their
octors which herbs they are taking and that doctors become
ufficiently informed to provide useful advice for their patients who
se herbs (2). It is therefore unfortunate that the Tachjian et al. (1)
eport was not more accurate and failed to discern between actual
afety risks, theoretical ones, and false reports.
